Discontinued — last reported Q2 '22
Sherwin-Williams Short-Term Borrowings increased by 98.0% to $2.38B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 32.1%, from $1.80B to $2.38B. Over 5 years (FY 2020 to FY 2025), Short-Term Borrowings shows an upward trend with a 554.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
High levels may indicate a reliance on short-term credit markets for operational cash flow, which can increase liquidity risk.
Short-term borrowings consist of debt obligations that are due within one year, excluding the current portion of long-te...
Varies by industry; pharmaceutical firms often maintain access to short-term credit for operational flexibility.
short_term_borrowings| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $762.10M | $709.40M | $763.50M | $1.74B | $2.01B | $945.20M | $978.10M | $1.48B | $806.20M | $338.60M | $374.20M | $1.26B | $1.36B | $915.50M | $662.40M | $1.80B | $1.71B | $1.85B | $1.20B | $2.38B |
| QoQ Change | — | -6.9% | +7.6% | +127.9% | +15.7% | -53.0% | +3.5% | +51.4% | -45.6% | -58.0% | +10.5% | +235.7% | +8.1% | -32.6% | -27.6% | +171.5% | -5.1% | +8.2% | -35.0% | +98.0% |
| YoY Change | — | — | — | — | +164.0% | +33.2% | +28.1% | -14.9% | -59.9% | -64.2% | -61.7% | -15.2% | +68.5% | +170.4% | +77.0% | +43.2% | +25.6% | +101.7% | +81.2% | +32.1% |